Session: MON 327-337-Neuroendocrine Tumors
Poster Board MON-329
We report the results of a retrospective and prospective study regarding 54 patients (27 M, 27 F, median age 60 years) affected by neuroendocrine tumor, that came to our observation consecutively between 2005 and 2009. Twenty-six were affected by GEP-NETs, 27 by lung NETs and 2 patients presented with metastases from occult primary tumor. Treatment options and response to treatment have been evaluated according to the new classification of NETs (WHO 2010), that provides a grading system based on Ki-67 labeling index and mytotic count. The study population, according to this classification, has been divided into three distinct categories: G1 (38 patients), G2 (14 patients) and G3 (2 patients). Our results showed that the tumor grading is the most significant predictor of outcome. The survival curve showed a clear distinction in terms of disease-free interval between the three classes of grading, although statistical significance was not reached between G2 and G3, probably because of the paucity of G3 cases.
Our results confirm that the approach to these tumors should be multidisciplinary and show, for the first time in an heterogeneous series, that an accurate histopathological evaluation including tumor grading is crucial for a proper and effective therapeutic choice.
Nothing to Disclose: AB, DI, FL, FP, GS, GT, MVR, FI, AL, MGB, PG, DD, GBD, CAMB, GR, AP, LD
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters